Abstract: Objective To observe the clinical effect of Liuweiwuling tablet combined with telbivudine in chronic patients with active hepatitis B related cirrhosis. Methods Total of 72 patients with active hepatitis B related cirrhosis were randomly divided into two groups, the treatment group (n = 36) received Liuweiwuling tablet combined with telbivudine; meanwhile the control group (n = 36) received only telbivudine. Both groups were treated for 24 weeks. Liver function, hepatitis B virus markers and undetectable rate of HBV DNA were tested before and after treatment. Results Compared with the control group, serum ALT and AST levels in the treatment group decreased significantly and there was statistical difference between the two groups (P ＜ 0.05). The undetectable rate of HBeAg, seroconversion rate of HBeAg/anti-HBe and the total effective rate in the treatment group were higher than that in the control group (P ＜ 0.05). Conclusions Liuweiwuling tablet combined with telbivudine therapy is more effective than telbivudine only for patients with active hepatitis B related cirrhosis and with lower incidence of adverse reactions. This combination therapy is an effective way for treating active hepatitis B related cirrhosis patients.